Search in:

OncoTargets and Therapy Volume 11, 2018 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Case Report

Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report

Wan He1 Department of Oncology, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, Guangdong 518020, China

Xiangmei Zhang2 Department of Pathology, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong 518112, China

Wenwen Li1 Department of Oncology, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, Guangdong 518020, China

Cheng Kong1 Department of Oncology, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, Guangdong 518020, China

Yuanyang Wang3 Department of Surgery, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, Guangdong 518020, China

Lianyu Zhu1 Department of Oncology, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, Guangdong 518020, China

Ruilian Xu1 Department of Oncology, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, Guangdong 518020, China

Guofang Deng4 Department of Pulmonary Medicine, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong 518112, China, [email protected]; [email protected]Correspondence[email protected] [email protected]

Peize Zhang4 Department of Pulmonary Medicine, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong 518112, China, [email protected]; [email protected]Correspondence[email protected] [email protected]

show all

Pages 7423-7427 | Published online: 24 Oct 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (24)

Yusuke Izutani, Yuki Ushimaru, Kazuhiro Nishikawa, Ryohei Kawabata, Nobuyoshi Ohara, Yuichiro Miyake, Sakae Maeda, Shin Nakahira, Ken Nakata, Atsushi Miyamoto & Yumiko Yasuhara. (2022) A Case of Unresectable Advanced Esophageal Cancer with Tuberculosis and Immune Thrombocytopenic Purpura Due to Nivolumabニボルマブにて結核と免疫性血小板減少性紫斑病を来した切除不能進行食道癌の1例. The Japanese Journal of Gastroenterological Surgery 55:8, pages 483-490.
Crossref

Kewei Liu, Dongpo Wang, Cong Yao, Min Qiao, Qing Li, Weicong Ren, Shanshan Li, Mengqiu Gao & Yu Pang. (2022) Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis. Frontiers in Immunology 13.
Crossref

Tommaso Morelli, Kohei Fujita, Gil Redelman-Sidi & Paul T Elkington. (2022) Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax 77:3, pages 304-311.
Crossref

Kin-Sang Lau, Ben Man-Fei Cheung, Ka-On Lam, Sum-Yin Chan, Ka-Ming Lam, Chun-Fai Yeung, Ivan Fan-Ngai Hung, Dora Lai-Wan Kwong, Chi-Chung Tong, To-Wai Leung, Mai-Yee Luk, Anne Wing-Mui Lee, Kwok-Keung Yuen & Victor Ho-Fun Lee. (2021) Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report. BMC Infectious Diseases 21:1.
Crossref

Gregory R. Stroh, Tobias Peikert & Patricio Escalante. (2021) Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area. Cancer Immunology, Immunotherapy 70:11, pages 3105-3111.
Crossref

Seongman Bae, Ye-Jee Kim, Min-ju Kim, Jwa Hoon Kim, Sung-Cheol Yun, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sung-Han Kim, Sang-Ho Choi, Yang Soo Kim & Sang-Oh Lee. (2021) Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. Journal for ImmunoTherapy of Cancer 9:9, pages e002960.
Crossref

Marek Fol, Piotr Koziński, Jakub Kulesza, Piotr Białecki & Magdalena Druszczyńska. (2021) Dual Nature of Relationship between Mycobacteria and Cancer. International Journal of Molecular Sciences 22:15, pages 8332.
Crossref

Hyung Woo Kim, Ju Sang Kim & Sang Haak Lee. (2021) Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors – A nationwide population-based cohort study. Lung Cancer 158, pages 107-114.
Crossref

Ethan A. Burns, Ibrahim N. Muhsen, Kartik Anand, Jiaqiong Xu, Godsfavour Umoru, Abeer N. Arain & Maen Abdelrahim. (2021) Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors. Journal of Immunotherapy 44:3, pages 132-139.
Crossref

Aasir M. Suliman, Shaza A. Bek, Mohamed S. Elkhatim, Ahmed A. Husain, Ahmad Y. Mismar, M. Z. Sharaf Eldean, Zsolt Lengyel, Shereen Elazzazy, Kakil I. Rasul & Nabil E. Omar. (2020) Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review. Cancer Immunology, Immunotherapy 70:4, pages 935-944.
Crossref

Qianyun Shan & Hongyang Lu. (2021) Immune Checkpoint Inhibitors in Special Populations. Technology in Cancer Research & Treatment 20, pages 153303382110365.
Crossref

Yun-Bin Zhang, Shi-Jia Liu, Zhi-Dong Hu, Ji-Xue Zhou, Yin-zhen Wang, Bing Fang, Ka-Wing Wong & Fan Xia. (2020) Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis. Cancer Immunology, Immunotherapy 69:12, pages 2665-2671.
Crossref

Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye & Michael Boyle. (2020) Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 33:3.
Crossref

Jacob Zaemes & Chul Kim. (2020) Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature. European Journal of Cancer 132, pages 168-175.
Crossref

Yasuhiro Kato, Yasutaka Watanabe, Yuki Yamane, Hideaki Mizutani, Futoshi Kurimoto & Hiroshi Sakai. (2020) Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report. Immunotherapy 12:6, pages 373-378.
Crossref

Seonggyu Byeon, Jang Ho Cho, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park & Myung‐Ju Ahn. (2020) PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence. Cancer Medicine 9:7, pages 2352-2362.
Crossref

Minya Lu, Li Zhang, Yue Li, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiaoyan Si, Yingchun Xu & Li Zhang. (2020) Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thoracic Cancer 11:3, pages 805-809.
Crossref

Liku B Tezera, Magdalena K Bielecka, Paul Ogongo, Naomi F Walker, Matthew Ellis, Diana J Garay-Baquero, Kristian Thomas, Michaela T Reichmann, David A Johnston, Katalin Andrea Wilkinson, Mohamed Ahmed, Sanjay Jogai, Suwan N Jayasinghe, Robert J Wilkinson, Salah Mansour, Gareth J Thomas, Christian H Ottensmeier, Alasdair Leslie & Paul T Elkington. (2020) Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. eLife 9.
Crossref

Ewan A Langan, Victoria Graetz, Judith Allerheiligen, Detlef Zillikens, Jan Rupp & Patrick Terheyden. (2020) Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. The Lancet Oncology 21:1, pages e55-e65.
Crossref

Amalia Anastasopoulou, Dimitrios C. Ziogas, Michael Samarkos, John M. Kirkwood & Helen Gogas. (2019) Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. Journal for ImmunoTherapy of Cancer 7:1.
Crossref

Jacques Cadranel, Anthony Canellas, Lise Matton, Marie Darrason, Antoine Parrot, Jean-Marc Naccache, Armelle Lavolé, Anne-Marie Ruppert & Vincent Fallet. (2019) Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. European Respiratory Review 28:153, pages 190058.
Crossref

Ronwyn van Eeden, Bernardo L. Rapoport, Teresa Smit & Ronald Anderson. (2019) Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review. Frontiers in Oncology 9.
Crossref

Jiqiao Yang, Xiujing He, Qing Lv, Jing Jing & Hubing Shi. (2019) Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Frontiers in Pharmacology 10.
Crossref

. (2019) Antituberculars/pembrolizumab. Reactions Weekly 1735:1, pages 43-43.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report

Articles from other publishers (24)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report

Citations (24)

Articles from other publishers (24)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date